

July 17, 2012

## **Theravance to Report Second Quarter 2012 Financial Results on July 31, 2012**

SOUTH SAN FRANCISCO, Calif., July 17, 2012 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:[THR](#)) announced today that it will release financial results for the period ended June 30, 2012 after market close on Tuesday, July 31, 2012.

An accompanying conference call will be held at 5:00 p.m. Eastern Daylight Time. To participate in the live call by telephone, please dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting Theravance's web site at [www.theravance.com](http://www.theravance.com). To listen to the live call, please go to the web site 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the conference call will be available on Theravance's web site for 30 days through August 30, 2012. An audio replay will also be available through 11:59 p.m. Eastern Daylight Time on August 7, 2012 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers, and entering confirmation code 94655976.

### **About Theravance**

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Theravance's key programs include: RELVAR™/BREO™, LAMA/LABA (umeclidinium bromide (UMEC)/vilanterol (VI)) and MABA (Bifunctional Muscarinic Antagonist-Beta<sub>2</sub> Agonist), each partnered with GlaxoSmithKline plc, and its oral Peripheral Mu Opioid Receptor Antagonist (PμMA) program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit Theravance's web site at [www.theravance.com](http://www.theravance.com).

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

RELVAR™ and BREO™ are trademarks of the GlaxoSmithKline group of companies.

CONTACT: Michael W. Aguiar  
Senior Vice President and Chief Financial Officer  
650-808-4100  
[investor.relations@theravance.com](mailto:investor.relations@theravance.com)